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Abstract
Background: Cost-effectiveness acceptability curves (CEACs) describe the probability that a new
treatment or intervention is cost-effective. The net benefit regression framework (NBRF) allows
cost-effectiveness analysis to be done in a simple regression framework. The objective of the paper
is to illustrate how net benefit regression can be used to construct a CEAC.
Methods: One hundred patients referred for ambulatory monitoring with syncope or presyncope
were randomized to a one-month external loop recorder (n = 49) or 48-hour Holter monitor (n
= 51). The primary endpoint was symptom-rhythm correlation during monitoring. Direct costs
were calculated based on the 2003 Ontario Health Insurance Plan (OHIP) fee schedule combined
with hospital case costing of labour, materials, service and overhead costs for diagnostic testing and
related equipment.
Results: In the loop recorder group, 63.27% of patients (31/49) had symptom recurrence and
successful activation, compared to 23.53% in the Holter group (12/51). The cost in US dollars for
loop recording was $648.50 and $212.92 for Holter monitoring. The incremental cost-
effectiveness ratio (ICER) of the loop recorder was $1,096 per extra successful diagnosis. The
probability that the loop recorder was cost-effective compared to the Holter monitor was
estimated using net benefit regression and plotted on a CEAC. In a sensitivity analysis,
bootstrapping was used to examine the effect of distributional assumptions.
Conclusion: The NBRF is straightforward to use and interpret. The resulting uncertainty
surrounding the regression coefficient relates to the CEAC. When the link from the regression's
p-value to the probability of cost-effectiveness is tentative, bootstrapping may be used.
Background
Out patient ambulatory monitoring is often performed in
patients with syncope (e.g., fainting or passing out) that
present in the primary care setting to diagnose or exclude
an arrhythmia, a potentially serious etiology [1-6]. This
short-term monitoring device may take the form of an
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of monitoring is to obtain a symptom-rhythm correlation
during the monitored period (i.e., to have the monitoring
device actively record a patient experiencing symptoms).
Several studies have reported the diagnostic yield of the
two monitoring modalities, suggesting a higher yield from
the longer duration of monitoring provided by a loop
recorder [3,7-12]. One recent randomized trial confirmed
the higher diagnostic yield [5]. There is a lack of data
about the cost of investigation of syncope presenting in
the community. Referred and hospitalized patients are
known to generate costs estimated between $3,000 and
$25,000 dollars [13-19]. After a primary diagnostic trial
[5], we sought to establish the cost of investigation of
"community-acquired" syncope and to evaluate the cost-
effectiveness of the two monitoring strategies in a pro-
spective randomized trial [20].
A new health care treatment, intervention or technology is
cost-effective if (1) the extra cost of (2) an extra unit of
effect is less than (3) the decision maker's willingness to
pay for it. A cost-effectiveness analysis (CEA) can report
(1) and (2), representing two of the three pieces of infor-
mation necessary to determine cost-effectiveness. Specifi-
cally, an incremental cost-effectiveness ratio (ICER) is the
ratio of extra cost to extra effect (i.e., ∆C/∆E). Thus, a CEA
generates an estimate of the extra cost for an additional
unit of effect, but the merit of the trade-off is typically a
matter of opinion. In other words, the data are generally
silent on whether the extra effect is worth the extra cost.
For example, a new drug for multiple sclerosis may pro-
vide an extra quality adjusted life year (QALY) for
£35,000. The new drug is cost-effective if the decision
maker is willing to pay £35,000 or more for an extra
QALY. Thus the verdict of cost-effectiveness depends
upon the decision maker's willingness to pay (λ), a value
not known from the cost and effect data. There is addi-
tional uncertainty beyond the fact that λ is unknown. The
uncertainty comes from the fact that the sample ICER is a
statistical estimate. For example, if the true ICER is
£30,000 per QALY, the ICER estimate could be more or
less due to sampling variability. In fact, the multiple scle-
rosis drug with the ICER estimate of £35,000 per QALY
could have a true ICER of £30,000 per QALY. It would be
a mistake to conclude there is no chance that the drug is
cost-effective if λ = £31,000, for example.
The cost-effectiveness acceptability curve (CEAC) ele-
gantly handles both uncertainty problems. This paper,
building on recent work by Fenwick and colleagues [21],
illustrates how to use the net benefit regression framework
(NBRF) [22] to construct a CEAC. After a brief summary
of relevant statistical concepts, this paper uses clinical trial
data from a recently published CEA comparing external
loop recorders with Holter monitors for ambulatory mon-
itoring of syncope.
Methods
One hundred patients referred for ambulatory monitoring
with syncope or presyncope (hereafter described as syn-
cope) were randomized to a one-month external loop
recorder (n = 49) or 48-hour Holter monitor (n = 51).
Patients provided written informed consent, and the pro-
tocol was approved by the University of Western Ontario
Ethics Review Board. The primary endpoint was symp-
tom-rhythm correlation during monitoring. Direct costs
in Canadian dollars were calculated from the Ministry of
Health's perspective based on the 2003 Ontario Health
Insurance Plan (OHIP) fee schedule for professional fees
and on hospital case costing data for the calculation of
labour, materials, service and overhead for diagnostic test-
ing and related equipment. Costs were converted to US
Dollars using a conversion rate converted on July 20th,
2005 of ($1 USD = $1.21543 CAD) [20].
Loop recorders were both more costly and more effective
than Holter monitors. For the loop recorder, the cost in
US dollars was $648.50 and for the Holter monitor
$212.92 [20]. The extra cost of $435.58 for the loop
recorder was accompanied by a 39.74% increase of suc-
cess while monitoring (in the loop recorder group 31 of
49 or 63.27% of patients had symptom recurrence and
successful activation, compared to 12 of 51 or 23.53% in
the Holter group). The ICER estimate was $1096 per addi-
tional diagnosis. The CEAC finds purchase here as there is
uncertainty about the maximum a decision maker would
pay for an additional diagnosis coupled with the statisti-
cal variability inherent in trial data. As an alternative to
the method illustrated by Fenwick and colleagues [21], we
use the NBRF to show how to construct the CEAC.
The CEAC has been advocated for summarizing the results
of a CEA because it highlights the relationship between
the assessment of cost-effectiveness and the unknown λ
[23-27]. As originally described, the CEAC originates from
a Bayesian context; however, the CEAC can be given a fre-
quentist interpretation. For a given λ, the CEAC is equal to
one minus the one-sided significance level for testing the
null hypothesis that the "new treatment" is not cost-effec-
tive (i.e., the additional benefits are outweighed by the
additional costs) [25,28]. Under this frequentist frame-
work, the CEAC can be viewed as illustrating a decision
rule for rejecting the null hypothesis that the intervention
is not cost-effective.
Alternatively, the CEAC can be interpreted in a 'Bayesian'
fashion [23,24] as: the probability that an individual, with
a set of prior beliefs about the cost-effectiveness of the
new treatment, now believes the new treatment to be cost-Page 2 of 8
(page number not for citation purposes)
BMC Health Services Research 2006, 6:68 http://www.biomedcentral.com/1472-6963/6/68effective (i.e., the additional benefits outweigh the addi-
tional costs). While a Bayesian approach provides a well-
justified interpretation for a CEAC, it presents other
dilemmas. For example, there exist many 'Bayesian'
CEACs – namely one for every set of prior beliefs – with
no criteria for choosing between them. This is important
because every CEAC is 'correct' for its given prior. Thus,
the calculation of a Bayesian CEAC requires the specifica-
tion of the prior distribution of the cost-effectiveness data
before the data were collected. Typically as a reference case
scenario, it is common and convenient to use a 'non-
informative' prior which allows the data to overwhelm
prior beliefs. However, except in the simplest of examples
there is no agreement about the definition of a reference
prior distribution and many so-called non-informative
priors are not non-informative at all (see section 5.5.1 of
[29]). When using a 'non-informative' prior with the
NBRF (in this case assuming there is no reason to modify
the results of the data analysis), the Bayesian mechanics
work in the background and formal derivation of the pos-
terior distribution can be avoided. In other words, one can
run a net benefit regression and use the resulting parts to
illustrate the probability that a new treatment or interven-
tion is cost-effective (NB: The p-value itself does not pro-
vide an estimate of the probability of cost-effectiveness
when there is prior information. This is a fundamental
distinction between the interpretation of a p-value and a
posterior probability [30]. For a more comprehensive dis-
cussion about the use of genuine prior information in
cost-effectiveness analyses readers are referred to [31-33]).
The NBRF was introduced to facilitate the use of regres-
sion tools in economic evaluation [22]. Net benefit regres-
sion uses as the dependent variable, net benefit nbi =λ·effecti - costi from person-level effect (effecti) and cost
(costi) data (as a matter of preference, the analyst may use
net health benefits [34] instead of net monetary benefits
[35]). When ordinary least squares (OLS) is used to esti-
mate the simple linear regression
nbi = β0 + β1TX + ε
where TX is a "new treatment" indicator variable (e.g., TX
= 1 if the patient received a loop recorder and TX = 0 if the
patient received a Holter monitor), the coefficient esti-
mate of β1, call this b1, equals the difference in mean nb
for the loop and Holter groups. It can be shown [22] that
when this difference is greater than zero (i.e., when the
loop group has greater mean net benefits than the Holter
group), then ∆C/∆E < λ. In other words, if b1 > 0, then the
loop recorder is cost-effective relative to the Holter moni-
tor (or the incremental net benefit is positive). The statis-
tical uncertainty involving the cost and effect data is
expressed in the p-value for b1. The p-value for b1 can be
used to make the y-axis of the CEAC [22,25]; however,
caution must be exercised in two regards.
Using the NBRF and a Bayesian perspective, the CEAC
illustrates the probability that a "new treatment" is cost-
effective by graphing the probability that β1 > 0 as a func-
tion of λ. Most statistical packages have regression pro-
grams that report a two-sided p-value, but in this case a
one-sided probability is indicated. Because the two-sided
p-value is twice as much probability as is needed, it is nec-
essary to divide it by two (this converts the two-sided p-
value into a one-sided p-value). Figure 1 illustrates this
and the importance of checking the sign of b1. When b1 <
0, the probability that new treatment is cost-effective
equals the one-sided p-value, and when b1 > 0, the proba-
bility that new treatment is cost-effective equals one
minus the one-sided p-value. Thus when using the p-value
from a regression to make a CEAC, one must check that
one is using the one-sided p-value and that one is doing
the correct calculation given the sign of b1 (i.e., 1/2 p-
value of b1 when b1 < 0 or 1 - 1/2 p-value of b1 when b1 >
0). Lastly, because the p-value of a parametric analysis is
derived from a distributional assumption, non-parametric
methods like bootstrapping may offer better alternatives
when distributional concerns arise (e.g., the data do not
appear distributed normally or with constant variance).
Results
Each study participant who received a loop recorder
incurred costs of $648.50 and 31 of the 49 (63.27%) had
symptom recurrence and successful activation. In compar-
ison, the Holter monitors cost $212.92 for each study par-
ticipant and only 12 of the 51 (23.53%) experienced a
successful outcome. The NBRF was implemented by esti-
mating with OLS the regression
nbi = β0 + β1LOOP + ε
where LOOP is an indicator variable equaling one if the
patient received a loop recorder and zero if the patient
received a Holter monitor. Table 1 shows how the net
benefit statistic (nbi) was calculated for each person whenλ was set to $1000.
Table 2 presents the complete results of five net benefit
regressions using λ = $500, $1000, $1500, $2000 and
$2500. To illustrate how the CEAC can be computed
using net benefit regression, Table 3 lists regression esti-
mates of the LOOP indicator variable for λ = $500
through $3000 (the horizontal axis for the CEAC) as well
as the regression and bootstrap estimates of the probabil-
ity that the loop recorder is cost-effective (the vertical axis
for the CEAC). For λ < $1000, the estimate of the incre-
mental net benefit is negative (i.e., b1 < 0), so the quantity
to calculate for the CEAC's vertical axis is simply one halfPage 3 of 8
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Illustrating the relationship between the p-value for the "new treatment" indicator variable in a net benefit regression (i.e., b1the increm nta  net benefit) and the prob bility that a  t t t is cost-effectiveFigu e 1
Illustrating the relationship between the p-value for the "new treatment" indicator variable in a net benefit regression (i.e., 
b1the incremental net benefit) and the probability that a new treatment is cost-effective
BMC Health Services Research 2006, 6:68 http://www.biomedcentral.com/1472-6963/6/68of the two-sided p-value. For λ > $1000, the estimate of
the incremental net benefit is positive (i.e., b1 > 0), so the
quantity to calculate for the CEAC's vertical axis is one
minus one half of the two-sided p-value. Figure 2 illus-
trates the resulting CEAC. Because the p-value is based on
distributional assumptions that may not hold with small
sample sizes or non-constant variance, bootstrapping can
be used as a non-parametric alternative to obtain values
for the CEAC's vertical axis. For this example, we drew
1000 bootstrapped samples of n = 100 from our original
sample. The resulting estimates of the probability that the
incremental net benefit is positive are reported in the last
column of Table 3.
Discussion
A CEAC indicates a 50% chance of cost-effectiveness when
λ equals the sample estimate of the ICER [26]. The ICER
for the loop recorder was $1,096 per extra successful diag-
nosis. Table 3 shows that when λ is within $500 of the
ICER estimate, the probability of cost-effectiveness is
quite sensitive. For example, at λ = $500, the probability
that loop recorders are cost-effective is 0%, but at λ =
$1500 it is approximately 88%. Figure 2 illustrates this, as
the most dramatic gains in the height of the curve (from
0% to 88%) occur between λ = $500 and $1500. Alterna-
tively, the curve is mostly flat for λ < $ 500 and λ > $1500.
While we may never know the real value of λ, if it is
assumed to be near the low range of the costs generated by
referred and hospitalized patients (e.g., $3000 dollars),
there appears to be a good chance that loop recorders are
cost-effective.
As reflected in the last two columns of Table 3, the proba-
bility of cost-effectiveness calculated using the p-value was
nearly identical to that calculated using the bootstrapping
method. This finding may be related to the fact that the
cost data in this trial did not vary by patient within treat-
ment group. All patients receiving a loop recorder had
costs of $648.50 and all patients receiving a Holter moni-
tor had costs of $212.92. When both patient level costs
and effect data vary, net benefit regression can still be used
to construct a CEAC (i.e., the statistical uncertainty involv-
ing the cost and effect data is expressed in the p-value).
However, the assumptions necessary to use the p-value
may not hold; for example, the presence of skewness or
heteroskedasticity in the data suggests caution when using
the p-value. Indeed, for low values of λ, the almost inevi-
table non-normal distribution of costs can challenge the
assumptions made in using the p-value in the regression
approach. For this reason, empirical examples of the
NBRF typically use bootstrapping to generate CEACs [36-
38]. However, as noted by a reviewer, the bootstrap is not
necessarily robust, particularly in CEAs when there is also
concern about the use of parametric methods because of
skewness. In addition to the incremental net benefit (β1),
net benefit regression provides an estimate of the mean
net benefit of "usual care" (β0), the mean net benefit of
"new treatment" (β0 + β1) and also regression diagnostic
information (e.g., the residual errors and R2). Thus, the
NBRF facilitates using regression diagnostics (see the
"Regression Diagnostics" section and Figure 6 in [22]) to
improve the quality of economic evaluations.
Conclusion
The NBRF provides a way for economic evaluations to use
the variety of tools that have been developed for regres-
sion. For any value of λ, net benefit regression produces a
cost-effectiveness estimate, and the CEAC produces a cost-
Table 2: Simple net benefit regression estimates (N = 100)a
Explanatory variables λ = $500b coefficient 
(p-value)
λ = $1000 coefficient 
(p-value)
λ = $1500 coefficient 
(p-value)
λ = $2000 coefficient 
(p-value)
λ = $2500 coefficient 
(p-value)
Constant term -95.27 (0.004) 22.37 (0.728) 140.02 (0.149) 257.67 (0.047) 375.32 (0.021)
LOOP -236.90 (<0.001) -38.22 (0.678) 160.46 (0.246) 359.14 (0.053) 557.82 (0.017)
R-squared 0.2143 0.0018 0.0137 0.0377 0.0570
a The treatment indicator variable LOOP = 1 for the Loop recorder and 0 for the Holter monitor.
b All monetary figures are in US dollars.
Table 1: Construction of the dependent variable (net benefit) when λ = $1000
Net Benefit with λ = $1000 Number of Subjects Treatment Group Successful outcome
$1000 * 1 - $648.50 = $351.50 31 Loop recorder Yes
$1000 * 0 - $648.50 = - $648.50 18 Loop recorder No
$1000 * 1 - $212.92 = $787.08 12 Holter monitor Yes
$1000 * 0 - $212.92 = - $212.92 39 Holter monitor No
NOTE: All loop recorders cost $648.50 and all Holter monitors cost $212.92.Page 5 of 8
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Cost-effectiveness acceptability curve (CEAC) showing the probability that loop recorders are cost-effective compared to Hol-ter monitors over  range of values for willingness to pay for an addition l syncope diagnosisFigur  2
Cost-effectiveness acceptability curve (CEAC) showing the probability that loop recorders are cost-effective compared to Hol-
ter monitors over a range of values for willingness to pay for an additional syncope diagnosis.
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Table 3: Using the net benefit regression results to create a cost-effectiveness acceptability curve (CEAC) with a comparison to 
bootstrapping the probability of cost-effectiveness
λ Treatment Indicator Coefficient One sided p-value Probability of cost-effectiveness 
(regression)
Probability of cost-effectiveness 
(bootstrapping)
Estimate p-value
$500 -236.90 <0.001 ≈ 0.000 0% 0%
$750 -137.56 0.048 0.024 2% 2%
$1000 -38.22 0.678 0.339 34% 33%
$1250 61.12 0.595 0.298 70% 71%
$1500 160.46 0.246 0.123 88% 89%
$1750 259.80 0.108 0.054 95% 94%
$2000 359.14 0.053 0.027 97% 97%
$2250 458.48 0.028 0.014 99% 98%
$2500 557.82 0.017 0.009 99% 99%
$2750 657.16 0.011 0.006 99% 99%
$3000 756.50 0.007 0.004 100% 100%
BMC Health Services Research 2006, 6:68 http://www.biomedcentral.com/1472-6963/6/68effectiveness probability. To allow for the fact that the
analyst does not know the decision maker's λ, the hori-
zontal axis of a CEAC varies in the style of a sensitivity
analysis, and the statistical uncertainty about cost-effec-
tiveness is reflected on the vertical axis. This paper has
illustrated how the NBRF can be used to construct a CEAC.
When the link from a net benefit regression's p-value to
the probability of cost-effectiveness is tentative, boot-
strapping provides an alternative.
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